BioCentury | Nov 2, 2018
Company News

Takeda proposes divestment of Shire GI candidate, announces loans

...proposed to the European Commission a potential divestment of Crohn’s disease and ulcerative colitis candidate SHP647...
...34% to 48% and nearly double its overall revenues (see “Takeda Hits the Gas” ). SHP647...
...Tokyo:4502), Tokyo, Japan Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Gastrointestinal Jaime De Leon Entyvio, vedolizumab (MLN0002) SHP647, pf-00547659 Shire...
BioCentury | Mar 31, 2018
Strategy

Refashioning Takeda

...ClinicalTrials.gov have been terminated, and Shire does not include the program in its published pipeline. SHP647...
...exclusive, worldwide rights to the molecule from Pfizer Inc. in 2016. In Phase II testing, SHP647...
...Data from a Phase II trial in ulcerative colitis showed the three lowest doses of SHP647...
BioCentury | Aug 4, 2017
Company News

Shire evaluating neurology pipeline

...hereditary angioedema attacks. This half, the company plans to begin a Phase III trial of SHP647...
...mAb against plasma kallikrein (KLKB1), in 2016 through its acquisition of Dyax Corp. Shire in-licensed SHP647...
BioCentury | Aug 3, 2017
Company News

Shire evaluating neurology pipeline

...hereditary angioedema attacks. This half, the company plans to begin a Phase III trial of SHP647...
...mAb against plasma kallikrein (KLKB1), in 2016 through its acquisition of Dyax Corp. Shire in-licensed SHP647...
BioCentury | Jun 20, 2016
Company News

Pfizer, Shire deal

...Shire licensed worldwide rights to Pfizer’s PF-00547659 . The anti-human mucosal addressin cell adhesion molecule 1...
...colitis (UC) and Crohn’s disease. Shire said it is designing the Phase III program for PF-00547659...
BioCentury | Jun 15, 2016
Company News

Shire licenses IBD biologic from Pfizer

...Inc. (NYSE:PFE) granted Shire plc (LSE:SHP; NASDAQ:SHPG) global rights to inflammatory bowel disease (IBD) candidate PF-00547659...
...disease. Shire spokesperson Clotilde Houze said the company is designing the Phase III program for PF-00547659...
BioCentury | Sep 18, 2014
Translation in Brief

Translational tidbits

...also has the anti-human mucosal vascular addressin cell adhesion molecule 1 ( MADCAM-1 ) mAb PF-00547659...
Items per page:
1 - 7 of 7